全文获取类型
收费全文 | 821篇 |
免费 | 66篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 23篇 |
妇产科学 | 30篇 |
基础医学 | 61篇 |
口腔科学 | 173篇 |
临床医学 | 62篇 |
内科学 | 190篇 |
皮肤病学 | 14篇 |
神经病学 | 21篇 |
特种医学 | 14篇 |
外科学 | 123篇 |
综合类 | 7篇 |
预防医学 | 48篇 |
眼科学 | 22篇 |
药学 | 28篇 |
中国医学 | 2篇 |
肿瘤学 | 56篇 |
出版年
2024年 | 2篇 |
2023年 | 6篇 |
2022年 | 21篇 |
2021年 | 27篇 |
2020年 | 26篇 |
2019年 | 36篇 |
2018年 | 59篇 |
2017年 | 15篇 |
2016年 | 22篇 |
2015年 | 38篇 |
2014年 | 46篇 |
2013年 | 39篇 |
2012年 | 72篇 |
2011年 | 79篇 |
2010年 | 54篇 |
2009年 | 39篇 |
2008年 | 39篇 |
2007年 | 45篇 |
2006年 | 33篇 |
2005年 | 33篇 |
2004年 | 19篇 |
2003年 | 17篇 |
2002年 | 16篇 |
2001年 | 6篇 |
2000年 | 17篇 |
1999年 | 13篇 |
1998年 | 11篇 |
1997年 | 7篇 |
1996年 | 6篇 |
1995年 | 6篇 |
1994年 | 4篇 |
1993年 | 3篇 |
1992年 | 4篇 |
1991年 | 4篇 |
1990年 | 3篇 |
1989年 | 1篇 |
1988年 | 4篇 |
1987年 | 1篇 |
1986年 | 4篇 |
1985年 | 1篇 |
1984年 | 4篇 |
1983年 | 1篇 |
1979年 | 1篇 |
1971年 | 1篇 |
1968年 | 1篇 |
1967年 | 1篇 |
1966年 | 2篇 |
排序方式: 共有889条查询结果,搜索用时 15 毫秒
1.
We describe a 28-year-old white Caucasian man displaying many of the physical signs of ectodermal dysplasia (ED). An unusual finding was his presentation with xerostomia. Salivary gland imaging techniques revealed aplasia of both submandibular salivary glands and relatively small parotids. The case highlights that hypoplasia and aplasia of exocrine glands could be rare features of ED. In the management of ED, early detection of xerostomia is important to limit any potential damage to the already hypodontic dentition. 相似文献
2.
3.
A glycoprotein (gp-88) secreted by pseudorabies virus (PRV) infected cells was isolated and purified. Anti gp-88 antibodies were used to screen an expression library constructed in Escherichia coli using genomic PRV DNA. Two positive clones were identified and the cloned genetic information was used to localize the corresponding gene in the unique short region of the PRV genome. Antibodies to the glycoprotein were also used to identify the unglycosylated precursor as synthesized in an in vitro translation system. A major precursor of 65 kDa was detected. Although the glycoprotein described here was not found as a major structural glycoprotein of the virion, antibodies to gp-88 are able to neutralise viral activity in vitro. The possible relationship with known glycoproteins of PRV is discussed. 相似文献
4.
Wani T Kakru DK Shaheen R Nazir A Lone R Shakeel S Shah A 《Indian journal of pathology & microbiology》2004,47(1):76-77
Endocarditis is a rare complication of typhoid fever. We report a case in which Salmonella enterica serotype typhi was isolated from a case of endocarditis. The isolate was resistant to ampicillin, chloramphenicol and ciprofloxacin but sensitive to ceftriaxone, amikacin and gentamicin. 相似文献
5.
Humoral immune responses of Brucella-infected cattle, sheep, and goats to eight purified recombinant Brucella proteins in an indirect enzyme-linked immunosorbent assay. 总被引:1,自引:0,他引:1
下载免费PDF全文
![点击此处可从《Clinical and Vaccine Immunology : CVI》网站下载免费的PDF全文](/ch/ext_images/free.gif)
J J Letesson A Tibor G van Eynde V Wansard V Weynants P Denoel E Saman 《Clinical and Vaccine Immunology : CVI》1997,4(5):556-564
Brucellosis research is currently focused on the identification of nonlipopolysaccharide (LPS) antigens which could potentially be useful for the specific serologic diagnosis of brucellosis as well as for vaccinal prophylaxis. On the basis of previous reports, we selected eight Brucella proteins (OMP36, OMP25, OMP19, OMP16, OMP10, p17, p15, and p39) as candidate antigens to be further evaluated. The genes encoding these proteins were cloned, sequenced, and overexpressed in Escherichia coli. The recombinant proteins were purified with a polyhistidine tag and metal chelate affinity chromatography and evaluated in an indirect enzyme-linked immunosorbent assay (iELISA). The specificity of the iELISA was determined with sera from healthy cattle, sheep, and goats and ranged from 95 to 99%, depending on the recombinant antigen and the species tested. Sera from experimentally infected, and from naturally infected, animals were used to evaluate the sensitivity of the iELISA. The antiprotein antibody response was often delayed when compared to the anti-smooth LPS (S-LPS) response and was limited to animals which developed an active brucellosis infection (experimentally infected pregnant animals and sheep and goats from areas where brucellosis is still endemic). Among the recombinant antigens, the three cytoplasmic proteins (p17, p15, and p39) gave the most useful results. More than 80% of the animals positive in S-LPS serology were also positive with one of these cytoplasmic proteins alone or a combination of two of them. None of the recombinant antigens detected experimentally infected nonpregnant cows and sheep or naturally infected cattle. This study is a first step towards the development of a multiprotein diagnostic reagent for brucellosis. 相似文献
6.
Detection and subtyping of HIV-1 isolates with a panel of characterized monoclonal antibodies to HIV p24gag 总被引:12,自引:2,他引:12
M Tersmette I N Winkel M Groenink R A Gruters R P Spence E Saman G Van Der Groen F Miedema J G Huisman 《Virology》1989,171(1):149-155
A panel of monoclonal antibodies (Mabs) was used to analyze the number and localization of B-cell epitopes on human immunodeficiency virus (HIV) p24gag and the variability of these epitopes in sequential HIV isolates and in isolates from different geographical origin. The specificity of these Mabs was demonstrated by immunoblotting and radioimmunoprecipitation assays. Cross-inhibition experiments indicated the presence of at least five different epitopes on p24. Analysis with p24 recombinant products revealed that three of the Mabs to p24 were directed to epitopes localized on the C-terminal part. Four other Mabs were directed to epitopes localized on the N-terminal half of the protein. Anti-p24 Mabs were used to develop HIV p24 antigen-capture assays. Application of these assays in HIV isolation resulted in more efficient recovery of HIV. Serotyping of HIV-1 isolates with five anti-p24 Mabs demonstrated that 55/65 isolates recovered from Dutch and Belgian individuals, but only 4/9 HIV-1 African isolates, were recognized by all five Mabs. Five of nine Central African HIV-1 isolates were not reactive with at least one of these Mabs. The variability of p24 appeared to be predominantly localized on the N-terminal part of the protein. Lack of expression of antigenic determinants on p24 was shown to be independent of culture conditions. Moreover, an infectious molecular clone was shown to have the same serotype as the corresponding HIV isolate. The serotype of sequential isolates obtained from 17 individuals over a 1 1/2- to 2 1/2-year period did not change, suggesting a limited in vivo p24 variation over time. 相似文献
7.
Hamed Nikoupour MD Peyman Arasteh MD MPH Alireza Shamsaeefar MD Fardin Ghanbari MD Arash Boorboor MD Ali Mosa Jafar Almayali MD Mojtaba Shafiekhani PharmD Ph.D Pirouz Samidoust MD Reza Shahriarirad MD Alireza Shojazadeh MD Keivan Ranjbar MD Mohammad Hasan Darabi MD Sina Tangestanipour MD Seyed Morteza Hosseini MD Leila Zahiri MD Saman Nikeghbalian MD 《JPEN. Journal of parenteral and enteral nutrition》2022,46(4):946-957
8.
Saman K. Hashmi Katie Bergstrom Alison A. Bertuch Jenny M. Despotovic Eyal Muscal Fan Xia Weimin Bi Andrea Marcogliese Rosa Diaz 《Pediatric blood & cancer》2019,66(1)
Neutropenia in pediatric patients can be due to a variety of disorders. We describe two patients who underwent extensive evaluation over many years for arthralgias and moderate neutropenia of unclear etiology. Genetic testing identified a pathogenic variant in PSTPIP1 (proline‐serine‐threonine phosphatase‐interacting protein 1) in both patients. Markedly elevated inflammatory markers and zinc levels confirmed the rare diagnosis of PSTPIP1‐associated myeloid‐related proteinemia inflammatory (PAMI) syndrome, tailoring treatment. Neutropenia is common in patients with PAMI syndrome. Unique mutations seen in PAMI syndrome may account for the specific phenotypic features of this disorder. 相似文献
9.
Jasna E. Deluce Luisa Cardenas Aly-Khan Lalani Saman Maleki Vareki Ricardo Fernandes 《Current oncology (Toronto, Ont.)》2022,29(7):5054
Prostate cancer remains one of the leading causes of cancer death in men worldwide. In the past decade, several new treatments for advanced prostate cancer have been approved. With a wide variety of available drugs, including cytotoxic agents, androgen receptor axis-targeted therapies, and alpha-emitting radiation therapy, identifying their optimal sequencing remains a challenge. Progress in the understanding of the biology of prostate cancer has provided an opportunity for a more refined and personalized treatment selection process. With the advancement of molecular sequencing techniques, genomic precision through the identification of potential treatment targets and predictive biomarkers has been rapidly evolving. In this review, we discussed biomarker-driven treatments for advanced prostate cancer. First, we presented predictive biomarkers for established, global standard treatments for advanced diseases, such as chemotherapy and androgen receptor axis-targeted agents. We also discussed targeted agents with recent approval for special populations, such as poly ADP ribose polymerase (PARP) inhibitors in patients with metastatic castrate-resistant prostate cancer with homologous recombination repair-deficient tumors, pembrolizumab in patients with high levels of microsatellite instability or high tumor mutational burden, and prostate-specific membrane antigen (PSMA) directed radioligand theragnostic treatment for PSMA expressing tumors. Additionally, we discussed evolving treatments, such as cancer vaccines, chimeric antigen receptor T-cells (CAR-T), Bispecific T-cell engagers (BiTEs), other targeted agents such as AKT inhibitors, and various combination treatments. In summary, advances in molecular genetics have begun to propel personalized medicine forward in the management of advanced prostate cancer, allowing for a more precise, biomarker-driven treatment selection with the goal of improving overall efficacy. 相似文献
10.
Luisa M. Cardenas Jasna E. Deluce Shahrukh Khan Omar Gulam Saman Maleki Vareki Ricardo Fernandes Aly-Khan A. Lalani 《Current oncology (Toronto, Ont.)》2022,29(8):5426
While surgical resection has remained the mainstay of treatment in early-stage renal cell carcinoma (RCC), therapeutic options in the advanced setting have remarkably expanded over the last 20 years. Tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor (VEGF-TKIs) and anti-programmed cell death 1 (PD-1)/anti-programmed death-ligand 1 (PD-L1)-based immune checkpoint inhibitors (ICIs) have become globally accepted options in the upfront metastatic setting, with different ICI-based combination strategies improving overall survival compared to single-agent Sunitinib. Although some patients benefit from long-term responses, most eventually develop disease progression. Ongoing efforts to better understand the biology of RCC and the different mechanisms of acquired resistance have led to the identification of promising therapeutic targets. Belzutifan, a novel agent targeting the angiogenic pathway involving hypoxia-inducible factors (HIFs), has already been approved for the treatment of early-stage tumors associated with VHL disease and represents a very promising therapy in advanced RCC. Other putative targets include epigenetic regulation enzymes, as well as several metabolites such as adenosine, glutaminase and tryptophan, which are critical players in cancer cell metabolism and in the tumor microenvironment. Different methods of immune regulation are also being investigated, including CAR-T cell therapy and modulation of the gut microbiome, in addition to novel agents targeting the interleukin-2 (IL-2) pathway. This review aims to highlight the emergent novel therapies for RCC and their respective completed and ongoing clinical trials. 相似文献